Chenxiang Tang
Chief Executive Officer Circode Biomed
Seminars
Tuesday 26th May 2026
Structuring RNA Design, Manufacturing & Regulatory Planning to Accelerate IND Timelines & Reduce Development Risk
Advancing novel RNA therapeutics requires early, aligned decisions that strengthen manufacturability and regulatory readiness. This workshop provides a practical framework for designing circular and self-amplifying RNA constructs, anticipating CMC risks and building streamlined development paths that reduce rework and accelerate IND timelines.
This workshop will gather experts to discuss:
- Accelerate IND timelines by applying structured design principles that cut construct development cycles and improve potency/durability.
- Prevent scale-up failures by identifying manufacturability and CMC risks early, ensuring GMP consistency and reducing costly rework.
- Minimize IND deficiencies by aligning regulatory expectations with analytical and CMC strategies, reducing late-stage surprises.
- Unify design, manufacturing, and regulatory teams to enable faster decision-making and reduce development bottlenecks.
This workshop is for:
R&D leaders, CMC teams, program directors, regulatory strategists and platform developers seeking a more predictable and accelerated path from sequence design to IND
Wednesday 27th May 2026
Demonstrating First-in-Human Clinical Translation of Circular RNA Therapeutics in Ischemic Disease
11:00 am
- Validate circular RNA as a clinically viable therapeutic modality by sharing global first-in-human dosing experience and early clinical insights from ischemic disease programs
- De-risk indication and modality selection by translating preclinical durability, expression, and safety data into real-world clinical decision-making frameworks
- Inform next-generation RNA development strategies by extracting early lessons on dosing, delivery, and trial design from one of the field’s first clinical programs
